ArticleJTO clinical and research reports2023

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab.

Katherine E R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.